Protagonist Therapeutics, Inc. PTGX

US Biotechnology

$136.88 ▲ +0.72% (+$0.98)

Open $135.11

Prev Close $135.90

Day Range $134.21 – $137.97

52W Range $76.70 – $160.81

Market Cap $8.79B

P/E (TTM) 105.91

Beta 1.24

EPS (TTM) $1.04

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2016-08-11
Shares Out.	64,710,000
Website	protagonist-inc.com/ ↗
Phone	13026365401
Employees	141
Revenue	$213.5M
Gross Profit	$213.5M
Net Income	$162.8M
Total Assets	$885.5M
Total Liabilities	$44.0M
Equity	$841.5M

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Protagonist Therapeutics, Inc. is a publicly traded company under the ticker symbol PTGX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.